Invivyd (NASDAQ:IVVD) Insider Jill Andersen Sells 32,771 Shares

Invivyd, Inc. (NASDAQ:IVVD) insider Jill Andersen sold 32,771 shares of Invivyd stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $1.54, for a total transaction of $50,467.34. Following the completion of the sale, the insider directly owned 216,675 shares of the company’s stock, valued at approximately $333,679.50. The trade was a 13.14% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Jill Andersen also recently made the following trade(s):

• On Wednesday, February 18th, Jill Andersen sold 34,939 shares of Invivyd stock. The stock was sold at an average price of $1.58, for a total transaction of $55,203.62.

Invivyd Trading Up 6.5%

NASDAQ IVVD traded up $0.10 during trading on Wednesday, hitting $1.65. 1,468,415 shares of the company traded hands, compared to its average volume of 3,015,442. Invivyd, Inc. has a 12 month low of $0.46 and a 12 month high of $3.07. The business has a fifty day simple moving average of $2.19 and a 200 day simple moving average of $1.75. The company has a market capitalization of $384.65 million, a P/E ratio of -3.51 and a beta of 0.60.

Institutional Investors Weigh In On Invivyd

Several large investors have recently modified their holdings of IVVD. Janus Henderson Group PLC raised its stake in Invivyd by 28.2% during the fourth quarter. Janus Henderson Group PLC now owns 32,543,142 shares of the company’s stock worth $80,870,000 after acquiring an additional 7,160,065 shares in the last quarter. Perceptive Advisors LLC bought a new stake in shares of Invivyd in the 4th quarter worth about $53,809,000. BVF Inc. IL bought a new stake in shares of Invivyd in the 4th quarter worth about $48,227,000. RA Capital Management L.P. acquired a new stake in shares of Invivyd during the 3rd quarter worth about $18,831,000. Finally, ADAR1 Capital Management LLC acquired a new stake in shares of Invivyd during the 3rd quarter worth about $8,108,000. 70.36% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have commented on the company. Zacks Research upgraded Invivyd from a “strong sell” rating to a “hold” rating in a report on Thursday, November 13th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Invivyd in a research note on Monday, December 29th. D. Boral Capital reiterated a “hold” rating on shares of Invivyd in a report on Tuesday, November 25th. BTIG Research reissued a “buy” rating on shares of Invivyd in a research report on Wednesday, January 21st. Finally, HC Wainwright raised their price target on Invivyd from $5.00 to $10.00 and gave the company a “buy” rating in a research report on Friday, October 31st. Three research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $8.00.

Key Stories Impacting Invivyd

Here are the key news stories impacting Invivyd this week:

• Neutral Sentiment: Multiple Form 4 filings disclose open?market sales (no new corporate/clinical announcements). The disclosures are routine SEC insider-sale filings rather than earnings or clinical-data releases. Representative SEC Filing
• Neutral Sentiment: Aggregate size and liquidity context — filings show insiders sold a total of over ~220,000 shares across Feb. 17–18 (multiple executives, see items below). Today’s volume (?1.47M) is below the stock’s 3M average, which can amplify price moves on relatively modest buying or selling flows.
• Negative Sentiment: Jill Andersen — sold 32,771 shares on 2/17 at ~$1.54 and 34,939 shares on 2/18 at ~$1.58; filings show a double?digit percentage reduction in her holdings. SEC Filing – Jill Andersen
• Negative Sentiment: Timothy Edward Lee — sold 19,663 shares on 2/17 at ~$1.54 and 20,964 on 2/18 at ~$1.58; each sale reduced his ownership by ~12–15%. SEC Filing – Timothy Lee
• Negative Sentiment: William E. Duke (CFO) — sold 19,663 shares on 2/17 at ~$1.54 and 20,964 on 2/18 at ~$1.58; filings show ~13–16% reductions in his holdings. SEC Filing – William Duke
• Negative Sentiment: Julie Green — sold 19,663 shares on 2/17 at ~$1.54 and 20,964 on 2/18 at ~$1.58; each sale trimmed her stake by ~13–16%. SEC Filing – Julie Green
• Negative Sentiment: Robert D. Allen III — sold 18,189 shares on 2/17 at ~$1.54 and 19,392 on 2/18 at ~$1.58; filings show ~12–14% reductions in his holdings. SEC Filing – Robert Allen

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.